Observational study about the prognostic implication of chromosomal and genetic alterations in adult acute myeloid leukemia. -JALSG AML209 Genetic Study (AML209-GS)

Not Applicable

• Conditions: Adult acute myeloid leukemia

• Registration Number: JPRN-UMIN000003432
• Lead Sponsor: Japan adult leukemia study group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-01
• Study Completion: 2020-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 1826

Inclusion Criteria

Not provided

Exclusion Criteria

1.The patients who had received chemotherapy, irradiation or hematopoietic stem cell transplantation against acute leukemias of ambiguous lineage, myeloproliferative neoplasms, myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. 2.The patients with natural killer cell lymphoblastic leukemia / lymphoma. 3.The patients with active cancer. 4.The patients who developed myocardial infarction within 1 year. 5.The patients with diabetes which is uncontrollable even with insulin. 6.The patients with active infection. 7.The patients with liver cirrhosis. 8.The patients who have the past history of renal dysfunction. 9.The patients with deep vein thrombosis requiring the treatment. 10.The patients with psychological disease. 11.The women who is or may be in pregnancy. 12.The HBV antigen or HIV antibody positive patients.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-free survival in each genotype.